The present review assessed the evidence on risk factors for the occurrence of adverse health outcomes after discharge (i.e. unplanned readmission or adverse drug event after discharge) that are potentially modifiable by clinical pharmacist interventions. The findings were compared with patient characteristics reported in guidelines that supposedly indicate a high risk of drug-related problems. First, guidelines and risk assessment tools were searched for patient characteristics indicating a high risk of drug-related problems. Second, a systematic PubMed search was conducted to identify risk factors significantly associated with adverse health outcomes after discharge that are potentially modifiable by a clinical pharmacist intervention. After the PubMed search, 37 studies were included, reporting 16 risk factors. Only seven of 34 patient characteristics mentioned in pertinent guidelines corresponded to one of these risk factors. Diabetes mellitus (n = 11), chronic obstructive lung disease (n = 9), obesity (n = 7), smoking (n = 5) and polypharmacy (n = 5) were the risk factors reported most frequently in the studies. Additionally, single studies also found associations of adverse health outcomes with different drug classes {e.g. warfarin [hazard ratio 1.50; odds ratio (OR) 3.52], furosemide [OR 2.25] or high beta-blocker starting doses [OR 3.10]}. Although several modifiable risk factors were found, many patient characteristics supposedly indicating a high risk of drug-related problems were not part of the assessed risk factors in the context of an increased risk of adverse health outcomes after discharge. Therefore, an obligatory set of modifiable patient characteristics should be created and implemented in future studies investigating the risk for adverse health outcomes after discharge.
Introduction
Patients at hospital discharge are prone to adverse health outcomes early thereafter [i.e. unplanned readmission or occurrence of adverse drug events (ADEs)]. After hospital discharge, 13-30% of all patients suffer from ADEs and, in the US, 16.5-19 .6% of all Medicare beneficiaries were readmitted unplanned within 30 days after discharge, at an estimated expense of $17.4 billion [1] [2] [3] [4] [5] .
Considerable evidence suggests that adverse health outcomes after discharge can be reduced by restructuring the discharge process [6] . Successful interventions include the establishment of multidisciplinary teams, intensive discharge planning, patient education on diseases and drugs, medication reconciliation and management, timely communication with primary care providers, and followup after discharge by home visits or telephone calls [7] [8] [9] [10] . Sometimes, clinical pharmacists were integrated into discharge processes [11] [12] [13] [14] [15] [16] ; however, most pharmaceutical interventions are considered to be particularly staff intensive and time consuming (e.g. medication reconciliation and medication education are considered to require about 10-90 min per patient [17, 18] ) and, hence, should be restricted to patients who are likely to benefit from these services [17, 18] .
One of the early publications mentioning patient characteristics suitable for targeting pharmacy services at was the World Health Organization (WHO) report on the role of the pharmacist in the healthcare system, published in 1994 [19] . Since then, different approaches, such as the care risk assessment tool of the National Health Service Scotland [20] , have been developed to identify patients who are likely to benefit most from medication-oriented interventions [20] [21] [22] [23] [24] . To direct costly and resource-intensive pharmacist discharge interventions towards the most susceptible patient populations, a set of modifiable patient characteristics that reflect a high risk of adverse health outcomes after discharge is needed.
Several guidelines list the characteristics of patients who present a high risk of drug-related problems, although their grade of evidence, as well as their applicability in the discharge setting, remains unclear. In order to create a set of evidence-based risk factors for adverse health outcomes that can be favourably influenced by clinical pharmacist interventions, we conducted a review of studies investigating risk factors for adverse health outcomes.
Methods
We carried out a thorough review of the literature and assessed the evidence on risk factors for the occurrence of postdischarge adverse health outcomes reaching significance in multivariate models. Included risk factors had to be potentially modifiable by clinical pharmacist interventions.
Some guidelines and risk assessment tools list patient characteristics associated with a high risk of drug-related problems, and are used to prioritize patients for medication safety interventions in primary and secondary care. As these patient characteristics initially were not designed to predict a high risk of readmission, we compared the findings from the literature search with these characteristics, in order to investigate the evidence on their transferability to the discharge setting.
In the following, all factors with a high risk of adverse health outcomes which were found in the literature search are referred to as 'risk factor', whereas the term 'patient characteristics' refers to characteristics listed in guidelines.
Definition of the modifiability of a patient characteristic (guideline search) or risk factor (PubMed search) by a clinical pharmacist A clinical pharmacist intervention was defined as medication reconciliation, medication review, counselling or postdischarge telephone interview [8, 15, 25] . Consequently, a risk factor or a patient characteristic was judged 'potentially modifiable' by a clinical pharmacist intervention if the following criteria were applicable: (i) they could be mitigated by providing drug treatment-related information on indications and contraindications, drug interactions, dosage, proper drug handling, monitoring or possible ADE; or (ii) they referred to a disease or patient status that was considered to be modifiable by a clinical pharmacist intervention in previous studies (i.e. diabetes mellitus, chronic obstructive pulmonary disease (COPD), asthma, as well as smoking and obesity) [26] [27] [28] [29] [30] . By contrast, other comorbidities and surrogates such as chronic kidney disease and elevated serum creatinine levels as sole risk factors or patient characteristics were regarded as unalterable because a clinical pharmacist intervention was not likely to improve disease status. Drug use that was a surrogate parameter for disease severity rather than inappropriate drug treatment was excluded; pertinent examples are steroids in inflammatory bowel disease or immunosuppressant drugs in transplantation patients. These drugs were defined as unalterable risk factors, unless another drug of the same drug class was available, with evidence of a lower risk of adverse health outcomes. Drugs or drug classes causing adverse health outcomes because of poor monitoring or inappropriate dosing were judged as modifiable [e.g. warfarin bleeding due to infrequent international normalized ratio (INR) monitoring] as well as drugs or drug classes without a clear indication.
Identification of modifiable patient characteristics (guideline search) associated with drug-related problems
First, open-access guidelines or risk assessment tools to improve medication safety in the English or German language were searched purposefully on the internet by one reviewer (B.M.). Therefore, the official websites of international expert associations, professional bodies and health services, such as the American Society of Hospital Pharmacists, Royal Pharmaceutical Society, Society of Hospital Pharmacists Australia, National Health Service UK and others, were searched. Second, an open internet search was carried out using keywords including 'risk factor', 'drugrelated problem', 'adverse drug events', 'risk tool', 'risk assessment' and 'guideline' in multiple combinations.
Subsequently, identified open-access guidelines were screened for patient characteristics indicating a high risk of drug-related problems.
Two reviewers (B.M., H.M.S.] independently judged the reported patient characteristics as 'likely to be modifiable', 'potentially modifiable' or 'not modifiable' by a clinical pharmacist intervention; if consensus was not reached, a third reviewer served as adjudicator (T.M.). With this guideline search, a set of patient characteristics was created which is already in use for prioritizing patients for medication safety interventions in primary and secondary care.
Identification of modifiable risk factors (PubMed search) for adverse health outcomes after hospital discharge
To identify risk factors associated with adverse health outcomes after discharge, a literature search and data synthesis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement [31] . In July 2016, PubMed was searched using the following search terms: 'risk factors'[All Fields] AND ['patients'(MeSH Terms) OR 'patients'(All Fields) OR 'patient'(All Fields)] AND ['DrugRelated Side Effects and Adverse Reactions'(MeSH) OR 'Patient Readmission'(MeSH)]'. Other terms such as 'predictor' were tested during the development phase of the search term but were not included in the final search strategy because fewer and less relevant results were found in pilot evaluations. There was no time restriction applied to the search.
Study selection. First, all titles were screened for inclusion or exclusion. Of these included titles, all abstracts were screened. When no abstract was available, the full text was read. Finally, all full texts of the included abstracts were read independently. Screening of the titles, abstracts and full texts was conducted in the same manner by two out of four reviewers (B.M., T.M., A.F.J.S., H.M.S.). For inclusion or exclusion, a consensus was needed. When consensus was not reached, a third reviewer served as adjudicator and made the decision, after discussion within the group. All full texts meeting the eligibility criteria were included in the review.
Eligibility criteria. Included studies needed to investigate risk factors for adverse health outcomes (i.e. unplanned readmission or ADE after discharge) that were considered potentially modifiable by the intervention of a clinical pharmacist. Readmission was defined as the transfer from all primary care settings (including long-term care and nursing homes) to an inpatient setting after prior hospitalization without any time restrictions. An extensive timeframe was used to gather data on as many potential risk factors as possible, even though, in some cases, causal relationships might have been unlikely. Studies had to be original research articles in the English or German language, reporting data from an adult patient population (≥18 years of age). All patient populations were included, except populations mainly consisting of homeless people, psychiatric patients and cancer patients, in whom healthcare and transitions of care are particularly complex, which means that identified risk factors are of low transferability to other patient populations. Case reports, case series, comments and expert opinions were excluded as ineligible research papers. Systematic reviews were screened and primary studies were included when eligible. Studies including as their outcome ADEs occurring before or during the index hospitalization were not eligible because of the different settings and the assumed low transferability to the posthospitalization healthcare situation. Only risk factors that significantly (P < 0.05) contributed to the outcome in multivariate models were included, and risk factors only tested in univariate analyses or not reaching statistical significance were excluded.
Data collection and analysis. The following data were extracted into a predefined data extraction sheet by one author (B.M.) and verified by two reviewers (T.M., H.M.S.): Country and year of publication, study design (e.g. retrospective cohort study, case-control study), specialty (e.g. cardiology, orthopaedic surgery) and patient population (e.g. heart failure patients >65 years of age), statistics (e.g. statistical model building, univariate and multivariate analysis, level of significance), definition of ADE (e.g. according to expert opinion, Naranjo score), data sources (e.g. analysis of claims data, analysis of patient records), definition and measurement of readmission (including time gap to index hospitalization) and identified risk factors (including odds ratios, hazard ratios or relative risk).
Bias assessment. Risk of bias was assessed independently by two out of three reviewers (B.M., T.M., H.S.) at study and outcome level using the Quality in Prognosis Studies (QUIPS) tool [32] . The overall risk of bias was judged as low when no more than one of the six categories (i.e. study participation, study attrition, risk factor measurement, outcome measurement, study confounding, statistical analysis and reporting) showed a moderate or high risk of bias; as moderate when more than one category was judged as having a moderate risk of bias; and as high when more than one category was judged as having a high risk of bias. The category 'study attrition' was used only for prospective studies because loss to follow-up was considered not to be applicable for retrospective studies. Grading of Recommendations Assessment, Development and Evaluation (GRADE) for prognostic factors was used to summarize the evidence for the risk factors reported most frequently in the included studies [33] . Given the applied inclusion criteria, the categories univariate analyses, study limitations and inconsistency were not applicable because studies with a high risk of bias, as well as studies with risk factors not significant in multivariate analyses, had already been excluded. Hence, in order to prevent overestimation, two categories (study limitations and inconsistency) were excluded from the final GRADE judgement.
Results

Identified modifiable patient characteristics associated with a high risk of drug-related problems
In total, five guidelines and one risk assessment tool from four countries were screened for patient characteristics indicating an elevated risk for drug-related problems. There were 34 patient characteristics listed, some of them describing rather general patient conditions -e.g. >4 comorbidities. Of these 34 patient characteristics, 15 were judged as likely to be modifiable by a clinical pharmacist intervention (e.g. inappropriate dosage), seven as potentially modifiable (e.g. high-risk drugs) and 12 as not modifiable (e.g. patient age) ( Table 1) .
Risk factors for adverse health outcomes after discharge from hospital, found in a PubMed search
The literature search identified 4673 studies after deduplication. Of these, 842 citations were eligible for abstract screening and 265 full texts were read. After full-text screening, 212 studies were excluded (the reasons are listed in Figure 1 ), leaving 53 records for bias assessment.
Study characteristics. The detailed results and characteristics are shown in Table 2 . The included studies dated from 1991 and 2015 and were mostly retrospective cohort studies (n = 28), while three were prospective cohort studies and six were retrospective case-control studies. No randomized controlled trials were identified.
The analysis of the included studies was based on databases from health insurance companies, quality improvement databases, data from hospital information systems, chart review and data prospectively gathered in patient interviews.
The studies were mainly conducted in surgical (n = 14) [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] and cardiac (n = 11) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] specialties. Other specialties included geriatrics [59] [60] [61] [62] [63] [64] , pneumology [65] [66] [67] , general internal medicine [68, 69] and intensive care [70] . Most studies evaluated readmission, only two studies focused on the occurrence of ADEs after discharge [34, 64] and one had the combined endpoint of readmission due to ADEs [62] .
Time to readmission was restricted mostly to 30 days after discharge (n = 15) [39, 43, 44, 48, 49, 52, 54, 55, 57, 60, 61, 63, 65, 69, 70] but some studies covered longer periods before readmission -e.g. 90-day readmission (n = 2) [58, 65] , and readmission within 1 year (n = 5) [50, 51, 55, 62, 66] , 2 years (n = 1) [53] or even 3 years (n = 1) [56] , and one study considered readmission without time restrictions [67] .
Risk factors significantly associated with adverse health outcomes in multivariate analyses. Diabetes mellitus (n = 11) [39-41, 47-49, 56, 58, 65, 68, 70] , obesity (n = 7) [35-37, 43-45, 49] and COPD (n = 9) [34, 38, 39, 45, 46, 48, 49, 61, 68] were the most frequently reported risk factors in the included articles (Table 2 ). Different categories of body mass index (BMI) (e.g. BMI 30-35, BMI >35) were considered in five studies [35, 36, 43, 44, 49] . Other risk factors at patient level were smoking [42, 46, 47, 52, 66] and elevated haemoglobin A1c (HbA1c) [54] . Besides these patient characteristics, the number of drugs [60, [62] [63] [64] 69] and any medication dosage changes 48 h prior to discharge [59] were significantly associated with adverse health outcomes. The number of drugs was identified as a predictive factor for adverse health outcomes in five studies, albeit with varying cut-off values, with the lowest threshold of >4 drugs per patient [64] up to a threshold of >13 drugs per patient [63] . Furthermore, there were some specific risk factors reported at medication level, such as the combination of a proton pump inhibitor with clopidogrel [50, 51] , antidiabetic drugs on postoperative days 4-7 [53] and the prescription of a calcium channel blocker after acute myocardial infarction [52] . In addition, high-dose beta-blockers at therapy initiation [57] , the use of psychotropic drugs and tranquilizers in COPD patients [66, 67] , the prescription of spironolactone in patients with renal impairment [55] , furosemide [64] and warfarin [62, 64] were all associated with adverse health outcomes.
Bias assessment. Of the 53 studies assessed, 16 studies were classified as having a high risk of bias and were therefore excluded from further evaluation (Table 3) . A low risk of bias was found in 13 studies, and 24 studies had a moderate risk of bias. The detailed characteristics of the bias assessment are shown in Tables S1, S2, S3 and S4). The grade of the evidence was evaluated for the risk factors diabetes mellitus, COPD, obesity and number of drugs, which had the highest level of evidence, whereas smoking was rated as having a low level of evidence. Results of the GRADE evaluation are shown in Table 4 .
Discussion
Exemplary guidelines or risk assessment tools compiled up to 34 distinct patient characteristics frequently associated with drug-related problems. In theory, about 22 of these characteristics appear to be modifiable, or at least potentially modifiable, by a clinical pharmacist intervention. With regard to the identification of susceptible patients potentially benefitting from these interventions at discharge, the present review identified seven characteristics (i.e. diabetes, polypharmacy, inappropriate dosage, changes in medication, contraindication, drug interaction and high-risk drugs) that were also associated with adverse health outcomes after discharge. The generalizability of the findings may be restricted to special patient populations because the majority of the studies were conducted in surgical and cardiac patient populations. However, in both settings, similar risk factors (i.e. diabetes mellitus, COPD and polypharmacy) were associated with adverse health outcomes. Moreover, analyses in both settings similarly failed to assess medication-related issues at a more detailed level (e.g. regarding dosages or typical drug-related problems) that would have allowed the characteristics indicated in the guidelines to be matched. However, we believe that surgical patients can also be negatively affected by medication-related aspects -e.g. with regard to anticoagulation or antibiotic treatment. Table 1 Reported patient characteristics of guidelines and risk assessment tools indicating the need for pharmaceutical care and the assessment of whether these characteristics are pharmaceutically modifiable
Patient characteristics
Rating of modifiability ABDA [24] DEGAM [23] HSC [22] NHS [20] SHPA [21] WHO [19] Specific patient characteristics 
Risk factors for adverse health outcomes after discharge
Disease-related risk factors
The comorbidities diabetes, COPD and obesity were the risk factors reported most frequently in the included studies. However, of all consulted guidelines, only the WHO report [19] states specific comorbidities as a patient characteristic indicating a particular need for pharmaceutical care. Many studies showed that pharmacists can positively influence the morbidity and quality of life of type 2 diabetes [26, 71] and COPD [27, 28, 72] patients, mainly by medication management, counselling patients on the appropriate handling of their drugs, and by increasing adherence [26] . Moreover, pharmacists were also successful propagators of weight reduction programmes Table 2 Results and study characteristics of included studies, sorted by specialty [47] 2015 ADE, adverse drug event, aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted risk ratio; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HbA1c, haemoglobin A1c; HR, hazard ratio; OR, odds ratio; PS, propensity score; RR, risk ratio; WHO, WHO, World Health Organization + = low risk of bias; 0 = moderate risk of bias Risk factors for adverse health outcomes after discharge Table 3 Study characteristics of studies excluded owing to high risk of bias, sorted by specialty [93] 2014 ADE, adverse drug event; aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; OR, odds ratio+ = low risk of bias; 0 = moderate risk of bias; À = high risk of bias Table 4 Results of Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment Risk factors for adverse health outcomes after discharge [26] . Owing to the designs of the included studies in the present review, it remains unclear whether the patients were readmitted on account of complications preventable by a clinical pharmacist or whether readmission were more likely to have occurred because of disease severity.
Drug therapy-related risk factors
Polypharmacy was repeatedly associated with adverse health outcomes [60, [62] [63] [64] 69] and is also reported in various guidelines [19] [20] [21] [22] [23] [24] . The probability of occurrence of drugdrug interactions and the prescription of potentially inappropriate drugs for older patients increases with an increasing number of prescribed drugs [73] [74] [75] . Pharmaceutical interventions might reduce inappropriate prescribing and polypharmacy. Yet, the causal relationship between clinical pharmacist interventions and a potential reduction in adverse health outcome rates remains unclear. The studies did not assess whether polypharmacy was indeed linked with inappropriate prescribing or just reflected an increased comorbidity status of the patients, suggesting that sicker patients have a higher risk of adverse health outcomes. Warfarin (risk of bleeding), furosemide (risk of electrolyte imbalances), spironolactone (risk of hyperkalaemia in renal impairment), calcium antagonists (risk of reflex tachycardia with short-acting dihydropyridines) and beta-blockers (risk of bradycardia) were the drugs or drug classes reported in the included studies that were also most likely to be causally related to adverse health outcomes. These drugs and drug classes are either listed as specific high-risk drugs [22] or not further specified high-risk drugs in the guidelines [19] [20] [21] 23] . Indeed, appropriate use of these drugs could be supported by pharmacotherapeutic interventions such as drug monitoring (e.g. INR monitoring) or advice on the appropriate choice of drugs and doses by clinical pharmacists. One study showed a decrease in drug-related readmissions by 80% due to the involvement of clinical pharmacists in patient care throughout the hospital stay [15] . This involved clinical pharmacists providing medication reconciliation at admission, giving advice on appropriate pharmacotherapy for the physicians, educating and counselling patients on their drugs, communicating with the primary care physicians and providing follow-up telephone calls [15] . Furthermore, clinical pharmacy services integrated into the care process (e.g. anticoagulation services [76] or betablocker dose titration guided by a clinical pharmacist [77] ) reduced the number of ADEs (e.g. bleeding) and emergency department visits; in addition, doses were more often appropriate and target doses were more often reached [76, 77] .
Disconnection between evidence and guidelines
Surprisingly, no other studies were found that addressed inappropriate use of other drugs or inappropriate dose selection in renal impairment as a risk factor for adverse health outcomes. For a considerable variety of characteristics mentioned in the guidelines, we found no correlating risk factor in the included studies. Such characteristics included wrong dosage in hepatic impairment [21] , non-adherence [21, 24] , difficulty with the medication delivery device [21, 23] , 12 or more doses of drugs per day irrespective of polypharmacy [21, 24] and a lack of treatment understanding [23] . In total, 15 of the characteristics mentioned in the guidelines were not identified as risk factors for adverse health outcomes after hospital discharge. However, five relevant risk factors -such as smoking, COPD, obesity, psychotropic drug use and tranquilizer use in COPD patients -were not found in the consulted guidelines, although patients have frequently benefited from interventions targeting these risk factors. On the one hand, the scope of the consulted guidelines was medication safety and a high risk of drug-related problems; the patient characteristics were not listed to predict the risk of readmission in the first place. On the other hand, the five risk factors are statistically associated with adverse health outcomes and not drugrelated problems, and thereby might not be listed in the consulted guidelines. Unfortunately, none of the studies had a suitable prospective design. Studies with a suitable design could be either prospective case-control studies or prospective cohort studies with adequate control groups. As a precondition, studies need to collect detailed data on drug therapy and relevant laboratory parameters. Further, these studies should report detailed information on comorbidities (e.g. COPD Gold III) as well as important specific characteristics of pharmacotherapy, such as adherence or the ability to use medication delivery systems. Moreover, studies should subsequently provide individual reasons for readmission, in order to prove causality for an observed association or directly provide a formal causality assessment of the reported endpoints. Some studies examined readmission in an extensive timeframe (e.g. 1 year [50, 51, 55, 62, 66 ], 2 years [53] ), so a causal relationship between risk factor and outcome seems unlikely and has a high risk of confounding. Hence, if diabetes was statistically associated with a higher readmission rate, it was not assessed whether the reason for readmission was indeed related to diabetes. Therefore, the reported association between outcome and identified risk factor was often solely of a statistical nature, such that not even a tentative conclusion about causality could be drawn.
Recommendations for future research
These findings imply the need for standardization in the design of studies investigating the risk of readmission. In order to assess the influence of risk factors on the individual readmission risk, the causes and reasons for individual readmissions, as well as a structured analysis of these, should be provided in studies investigating the predicted risk of adverse health outcomes. Moreover, the occurrence of adverse health outcomes should be restricted to a timeframe of 30 days. As the majority of the studies were conducted in particular specialties (e.g. cardiology or surgery), these studies only addressed risk factors that were relevant and within the scope of their field (e.g. surgical site infections), restricting the transferability of the findings to other patient populations, while the guidelines typically focused on specific patient populations. In order also to account for risk factors related to inappropriate drug treatment, in future studies a standardized set of patient characteristics from the consulted guidelines should be designed and implemented in the data collection process.
Study limitations
Over and above the reported limitations of the published evidence, there were also limitations due to the review design. First, the literature search was conducted using only one database. Furthermore, grey literature was not searched and articles written in a language other than English or German were not included, so it is likely that we did not capture all the available evidence. Yet, all other recommendations of the PRISMA statement were followed and a large number of studies were screened. Second, only articles with significant risk factors in multivariate analyses were included, which leaves the risk of inconsistency and the possibility that some risk factors were overestimated. We accounted for this potential weakness in the GRADE evaluation by downgrading the level of evidence for these risk factors, thus compensating for this weakness. Third, all of our evidence was collected from observational studies, some conducted with small sample sizes, an extensive timeframe for the occurrence of the outcome, and a moderate risk of bias. The potential methodological flaws of observational studies (e.g. small sample sizes and an uncertain causal relationship between risk factors and outcome) were accounted for by selecting rigorous inclusion and exclusion criteria, performing a strict bias assessment and applying the GRADE evaluation.
Conclusions
Although adjusted for known confounders in multivariate analyses, a considerable number of factors were still significantly associated with adverse health outcomes. However, these risk factors do not generally refer to patient characteristics used for prioritizing pharmacy services in primary or secondary care, which are not readily transferable to the discharge setting. Moreover, studies assessing adverse health outcomes after discharge have included only selected factors and confounders that might contribute to readmission and, as study designs are often retrospective, the causality of the relationship between outcomes and risk factors has not been established. Hence, future studies assessing the determinants of readmission should use an appropriate prospective design and always evaluate an obligatory set of patient and medication characteristics that are modifiable by pharmaceutical interventions. The individual cause of readmission should be scrutinized to enable a structured analysis of the relationship between adverse health outcomes and patient characteristics, and thus differentiate between important risk factors and mere confounders.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.
http://onlinelibrary.wiley.com/doi/10.1111/bcp.13318/suppinfo 
